Clinical Trial to Evaluate the Safety and Pharmacokinetics of YHP1903 in Healthy Volunteers

32 healthy subjects wil be randomized one of 2 groups in the same ratio. Subjects in group 1 will be administered "comparator" and "YHP1903" by cross-over design on day1, 8.

Subjects in group 2 will be administered "YHP1903" and "comparator" by cross-over design on day1, 8.

Inclusion criteria

• Healthy male/female aged 19 to 55 with body mass index(BMI) between 18.5 and 30kg/m2
• Acceptable medical history, physical examination, laboratory tests and EKG, during screening
• Subjects who has signed a written informed consent voluntarily,prior to any procedure, using a form that is approved by the local Institutional Review Board after detail explanation of the purpose, contents, and characteristic of the drug

Exclusion criteria

• History of clinically significant disease
• Sitting blood pressure meeting the following criteria at screening:

• 140 ≤ systolic blood pressure ≤90 (mmHg)
• 90 ≤ diastolic blood pressure ≤ 60 (mmHg)
• Have AST(SGOT) or/and ALT(SGPT) > 1.5 times of normal upper limit or Total bilirubin > 2.0 mg/dl at the time of screening
• Volunteers considered not eligible for the clinical trial by the investigator
• Administration of other investigational products within 6 month prior to the first dosing.